Longevity science is advancing rapidly — new clinical trial data, novel compounds, and updated frameworks emerge every month. But the gap between what the research shows and what reaches the public through media headlines and social media is enormous. Press releases routinely overstate findings, and the supplement industry amplifies preliminary data while ignoring negative replication studies.
This category serves as your filter for the longevity research landscape. We cover the landmark clinical trials (TAME, CALERIE, Dog Aging Project), evaluate the evidence behind prominent longevity frameworks (Peter Attia's Medicine 3.0, Bryan Johnson's Blueprint), assess longevity clinics and what they actually offer versus what the science supports, and review the pharmacological frontier — rapamycin, metformin, senolytics, and partial reprogramming. We also publish protocol guides for different life stages, budgets, and health conditions, translating the research into practical frameworks you can discuss with your physician.